These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19733126)

  • 1. Rectal morbidity after permanent interstitial brachytherapy for prostate cancer--impact of day 1 vs. day 30 computed tomography-based postimplant dosimetry.
    Pinkawa M; Piroth MD; Holy R; Klotz J; Nussen S; Borchers H; Heidenreich A; Eble MJ
    Brachytherapy; 2010; 9(1):1-7. PubMed ID: 19733126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
    Crook JM; Potters L; Stock RG; Zelefsky MJ
    Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seed displacements after permanent brachytherapy for prostate cancer in dependence on the prostate level.
    Pinkawa M; Gagel B; Asadpour B; Piroth MD; Klotz J; Borchers H; Jakse G; Eble MJ
    Strahlenther Onkol; 2008 Oct; 184(10):520-5. PubMed ID: 19016041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding.
    Mueller A; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1047-52. PubMed ID: 15234038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postimplant rectal dosimetry is not dependent on 103Pd or 125I seed activity.
    Merrick GS; Sylvester J; Grimm P; Allen ZA; Butler WM; Reed JL; Khanjian J
    Brachytherapy; 2011; 10(1):35-43. PubMed ID: 20153264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rectal function following prostate brachytherapy.
    Merrick GS; Butler WM; Dorsey AT; Galbreath RW; Blatt H; Lief JH
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):667-74. PubMed ID: 11020562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute patient-reported bowel quality of life and rectal bleeding with the combination of prostate external beam radiation, low-dose-rate brachytherapy boost, and SpaceOAR.
    Patel AK; Houser C; Benoit R; Smith RP; Beriwal S
    Brachytherapy; 2020; 19(4):477-483. PubMed ID: 32331976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planning based on postneedle volume with early dosimetric assessment is beneficial for Cesium-131 permanent prostate seed implantation.
    Smith RP; Beriwal S; Komanduri K; Gibbons E; Benoit R
    Brachytherapy; 2008; 7(3):237-41. PubMed ID: 18599357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.
    Ellis RJ; Zhou H; Kaminsky DA; Fu P; Kim EY; Sodee DB; Colussi V; Spirnak JP; Whalen CC; Resnick MI
    Brachytherapy; 2007; 6(2):149-56. PubMed ID: 17434109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary morbidity after permanent prostate brachytherapy - impact of dose to the urethra vs. sources placed in close vicinity to the urethra.
    Pinkawa M; Holy R; Piroth MD; Klotz J; Pfister D; Heidenreich A; Eble MJ
    Radiother Oncol; 2012 May; 103(2):247-51. PubMed ID: 22300607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy.
    Crook J; McLean M; Yeung I; Williams T; Lockwood G
    Brachytherapy; 2004; 3(2):55-60. PubMed ID: 15374536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Segmental dosimetry, toxicity and long-term outcome in patients with prostate cancer treated with permanent seed implants.
    Meyer A; Wassermann J; Warszawski-Baumann A; Baumann R; Machtens S; Karstens JH; Christiansen H; Merseburger A; Kuczyk MA; von Klot C
    BJU Int; 2013 May; 111(6):897-904. PubMed ID: 23305079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters.
    Pinkawa M; Fischedick K; Piroth MD; Gagel B; Borchers H; Jakse G; Eble MJ
    Strahlenther Onkol; 2006 Nov; 182(11):660-5. PubMed ID: 17072524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?
    Waterman FM; Dicker AP
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):293-9. PubMed ID: 12909246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer.
    Orio PF; Merrick GS; Galbreath RW; Butler WM; Lief J; Wallner KE
    Brachytherapy; 2012; 11(5):341-7. PubMed ID: 22561216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
    Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images.
    Ohashi T; Momma T; Yamashita S; Nagatsuma K; Kanai K; Kitagawa K; Takahashi S; Hanada T; Yorozu A; Shigematsu N
    Brachytherapy; 2012; 11(6):468-75. PubMed ID: 22330102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy.
    Merrick GS; Butler WM; Wallner KE; Murray BC; Allen Z; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):68-74. PubMed ID: 14697422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP; Moerland MA; Van Vulpen M; Wijrdeman HK; Battermann JJ
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):772-80. PubMed ID: 15964707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.